Please assess the completion status of the following clinical trial:

Trial Title: Intervention to End Recurrent Unscheduled Bleeding Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women age 18-45~* Implant placed \>90 days and \<3 years prior to enrollment~* Patient complaint of bothersome irregular bleeding with implant~* Willing to be abstinent or use condoms during study period~* Willing to complete 30-day bleeding diary~* Willing to be randomized to placebo or ulipristal acetate~* Ability to send/receive SMS text message~Exclusion Criteria:~* Non-English speaking~* Implant placed \>3 years prior to enrollment~* Contraindication to ulipristal acetate (current use of barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's Wort, topiramate, known or suspected pregnancy, hypersensitivity to active substance or excipients, uterine/cervical/ovarian/breast cancer, severe asthma insufficiently controlled by oral glucocorticoids)~* Inability or unwillingness to comply with medication protocol~* Inability or unwillingness to comply with bleeding diary~* Breastfeeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Ulipristal Acetate (Type: EXPERIMENTAL): 15mg ulipristal acetate (capsule) daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Identical placebo (capsule) daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).